CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

Linda Wittkop; Julie Arsandaux; Ana Trevino; Maarten Schim van der Loeff; Jane Anderson; Ard van Sighem; Jürg Böni; Françoise Brun-Vezinet; Vicente Soriano; Faroudy Boufassa; Norbert Brockmeyer; Alexandra Calmy; François Dabis; Inma Jarrin; Maria Dorrucci; Vitor Duque; Gerd Fätkenheuer; Robert Zangerle; Elena Ferrer; Kholoud Porter; Ali Judd; Nikolaos V Sipsas; Olivier Lambotte; Leah Shepherd; Catherine Leport; Charles Morrison; Cristina Mussini; Niels Obel; Jean Ruelle; Carolyne Schwarze-Zander; Anders Sonnerborg; Ramon Teira; Carlo Torti; Emilia Valadas; Celine Colin; Nina Friis-Møller; Dominique Costagliola; Rodolphe Thiebaut; Geneviève Chene; Sophie Matheron; COHERE in EuroCoord and ACHIeV2e Study Group

doi:10.1093/jac/dkx210

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

Linda Wittkop, Julie Arsandaux, Ana Trevino, Maarten Schim van der Loeff, Jane Anderson, Ard van Sighem, Jürg Böni, Françoise Brun-Vezinet, Vicente Soriano, Faroudy Boufassa, Norbert Brockmeyer, Alexandra Calmy, François Dabis, Inma Jarrin, Maria Dorrucci, Vitor Duque, Gerd Fätkenheuer, Robert Zangerle, Elena Ferrer, Kholoud PorterAli Judd, Nikolaos V Sipsas, Olivier Lambotte, Leah Shepherd, Catherine Leport, Charles Morrison, Cristina Mussini, Niels Obel, Jean Ruelle, Carolyne Schwarze-Zander, Anders Sonnerborg, Ramon Teira, Carlo Torti, Emilia Valadas, Celine Colin, Nina Friis-Møller, Dominique Costagliola, Rodolphe Thiebaut, Geneviève Chene, Sophie Matheron, COHERE in EuroCoord and ACHIeV2e Study Group

Department of Clinical Medicine

8 Citations (Scopus)

Abstract

Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).

Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.

Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.

Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.

Original language	English
Journal	The Journal of antimicrobial chemotherapy
Volume	72
Issue number	10
Pages (from-to)	2869-2878
ISSN	0305-7453
DOIs	https://doi.org/10.1093/jac/dkx210
Publication status	Published - 1 Oct 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jac/dkx210

dkx210.pdfFinal published version, 258 KB

Cite this

Wittkop, L., Arsandaux, J., Trevino, A., Schim van der Loeff, M., Anderson, J., van Sighem, A., Böni, J., Brun-Vezinet, F., Soriano, V., Boufassa, F., Brockmeyer, N., Calmy, A., Dabis, F., Jarrin, I., Dorrucci, M., Duque, V., Fätkenheuer, G., Zangerle, R., Ferrer, E., ... COHERE in EuroCoord and ACHIeV2e Study Group (2017). CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. The Journal of antimicrobial chemotherapy, 72(10), 2869-2878. https://doi.org/10.1093/jac/dkx210

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients : a multinational, multicohort European study. / Wittkop, Linda; Arsandaux, Julie; Trevino, Ana et al.

In: The Journal of antimicrobial chemotherapy, Vol. 72, No. 10, 01.10.2017, p. 2869-2878.

Research output: Contribution to journal › Journal article › Research › peer-review

Wittkop, L, Arsandaux, J, Trevino, A, Schim van der Loeff, M, Anderson, J, van Sighem, A, Böni, J, Brun-Vezinet, F, Soriano, V, Boufassa, F, Brockmeyer, N, Calmy, A, Dabis, F, Jarrin, I, Dorrucci, M, Duque, V, Fätkenheuer, G, Zangerle, R, Ferrer, E, Porter, K, Judd, A, Sipsas, NV, Lambotte, O, Shepherd, L, Leport, C, Morrison, C, Mussini, C, Obel, N, Ruelle, J, Schwarze-Zander, C, Sonnerborg, A, Teira, R, Torti, C, Valadas, E, Colin, C, Friis-Møller, N, Costagliola, D, Thiebaut, R, Chene, G, Matheron, S & COHERE in EuroCoord and ACHIeV2e Study Group 2017, 'CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study', The Journal of antimicrobial chemotherapy, vol. 72, no. 10, pp. 2869-2878. https://doi.org/10.1093/jac/dkx210

@article{13fe3dfc8ab24b5084f8e45c4819ae6b,

title = "CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study",

abstract = "Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.",

author = "Linda Wittkop and Julie Arsandaux and Ana Trevino and {Schim van der Loeff}, Maarten and Jane Anderson and {van Sighem}, Ard and J{\"u}rg B{\"o}ni and Fran{\c c}oise Brun-Vezinet and Vicente Soriano and Faroudy Boufassa and Norbert Brockmeyer and Alexandra Calmy and Fran{\c c}ois Dabis and Inma Jarrin and Maria Dorrucci and Vitor Duque and Gerd F{\"a}tkenheuer and Robert Zangerle and Elena Ferrer and Kholoud Porter and Ali Judd and Sipsas, {Nikolaos V} and Olivier Lambotte and Leah Shepherd and Catherine Leport and Charles Morrison and Cristina Mussini and Niels Obel and Jean Ruelle and Carolyne Schwarze-Zander and Anders Sonnerborg and Ramon Teira and Carlo Torti and Emilia Valadas and Celine Colin and Nina Friis-M{\o}ller and Dominique Costagliola and Rodolphe Thiebaut and Genevi{\`e}ve Chene and Sophie Matheron and {COHERE in EuroCoord and ACHIeV2e Study Group}",

note = "{\textcopyright} The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: [email protected].",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/jac/dkx210",

language = "English",

volume = "72",

pages = "2869--2878",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients

T2 - a multinational, multicohort European study

AU - Wittkop, Linda

AU - Arsandaux, Julie

AU - Trevino, Ana

AU - Schim van der Loeff, Maarten

AU - Anderson, Jane

AU - van Sighem, Ard

AU - Böni, Jürg

AU - Brun-Vezinet, Françoise

AU - Soriano, Vicente

AU - Boufassa, Faroudy

AU - Brockmeyer, Norbert

AU - Calmy, Alexandra

AU - Dabis, François

AU - Jarrin, Inma

AU - Dorrucci, Maria

AU - Duque, Vitor

AU - Fätkenheuer, Gerd

AU - Zangerle, Robert

AU - Ferrer, Elena

AU - Porter, Kholoud

AU - Judd, Ali

AU - Sipsas, Nikolaos V

AU - Lambotte, Olivier

AU - Shepherd, Leah

AU - Leport, Catherine

AU - Morrison, Charles

AU - Mussini, Cristina

AU - Obel, Niels

AU - Ruelle, Jean

AU - Schwarze-Zander, Carolyne

AU - Sonnerborg, Anders

AU - Teira, Ramon

AU - Torti, Carlo

AU - Valadas, Emilia

AU - Colin, Celine

AU - Friis-Møller, Nina

AU - Costagliola, Dominique

AU - Thiebaut, Rodolphe

AU - Chene, Geneviève

AU - Matheron, Sophie

AU - COHERE in EuroCoord and ACHIeV2e Study Group

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.

AB - Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL).Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients.Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.

U2 - 10.1093/jac/dkx210

DO - 10.1093/jac/dkx210

M3 - Journal article

C2 - 29091198

SN - 0305-7453

VL - 72

SP - 2869

EP - 2878

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 10

ER -

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this